Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Boehringer Ingelheim
McKesson
AstraZeneca
Express Scripts

Last Updated: October 20, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ILUVIEN

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Iluvien

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00770770 Fluocinolone Acetonide Intravitreal Inserts for Vein Occlusion in Retina Terminated Alimera Sciences Phase 2 2009-05-01 This study will assess the safety and efficacy of FA Intravitreal Inserts in subjects with macular edema secondary to RVO.
NCT01304706 Fluocinolone Acetonide in Diabetic Macular Edema (FAME) Extension Study Completed Alimera Sciences Phase 3 2011-04-01 This study will assess the safety and utility of the new inserter for the administration of ILUVIEN in subjects with diabetic macular edema.
NCT02359526 A Pilot Study on the Effect and Safety of Iluvien® in Chronic Diabetic Macular Edema Patients Active, not recruiting Association for Innovation and Biomedical Research on Light and Image Phase 4 2014-10-01 To provide treating physicians with experience with ILUVIEN as well as monitoring its safety (and effectiveness) in a real-life chronic diabetic macular edema (DME) patients judged insufficiently responsive to available therapies.
NCT02424019 Phase 4 IOP Signals Associated With ILUVIEN® Enrolling by invitation Alimera Sciences Phase 4 2015-04-01 This study will assess the safety in patients treated with ILUVIEN, with primary focus on IOP.
NCT02472366 A Non-Randomized, Open-Label, Single Center Phase 4 Study of the Effect and Safety of ILUVIEN® in Chronic Diabetic Macular Edema Patients Considered Insufficiently Responsive to Available Therapies (Laser, Anti-VEGF) With or Without Intravitreal Cort Completed Alimera Sciences Phase 4 2014-01-01 A phase 4 trial evaluating the effect and safety of ILUVIEN in chronic DME patients insufficiently responsive to available therapies.
NCT02902744 Fluocinolone Acetonide Insert (ILUVIEN®) for Diabetic Macular Edema (FAD) Study Recruiting Johns Hopkins University Phase 4 2016-09-01 Primary Objective: • To collect post-approval safety data related to intraocular pressure (IOP) after one or more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME). Secondary Objectives: • To collect visual and anatomic outcome data after one or more injections of Iluvien as standard of care in subjects with diabetic macular edema (DME).
NCT03784443 Randomized Control Trial on Combined Iluvien and Lucentis for Diabetic Macular Oedema Not yet recruiting Imperial College London Phase 2/Phase 3 2019-03-01 This trial investigated whether adding Iluvien sustained release steroid intravitreal eye implant at the beginning of regular anti-VEGF (anti Vascular Endothelial Growth Factor) intravitreal eye injection treatment for diabetic macular oedema would improve disease stability and reduce the need for regular anti-VEGF intravitreal eye injections over first two years. Diabetic macular oedema, accumulation of microscopic fluid at the back of the eye, is a major cause of poor vision in patients with diabetes. This is a double mask randomized control multisite trial, to be conducted at 10 NHS hospital eye clinics in England.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Iluvien

Condition Name

Condition Name for Iluvien
Intervention Trials
Diabetic Macular Edema 4
Macular Edema 1
Diabetic Macular Edema (DME) 1
Diabetes 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Iluvien
Intervention Trials
Macular Edema 7
Edema 6
Retinal Vein Occlusion 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Iluvien

Trials by Country

Trials by Country for Iluvien
Location Trials
United States 31
Puerto Rico 1
Portugal 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Iluvien
Location Trials
Georgia 2
Kentucky 2
Maryland 2
Massachusetts 2
New Hampshire 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Iluvien

Clinical Trial Phase

Clinical Trial Phase for Iluvien
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2/Phase 3 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Iluvien
Clinical Trial Phase Trials
Completed 2
Enrolling by invitation 1
Not yet recruiting 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Iluvien

Sponsor Name

Sponsor Name for Iluvien
Sponsor Trials
Alimera Sciences 4
Association for Innovation and Biomedical Research on Light and Image 1
Imperial College London 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Iluvien
Sponsor Trials
Industry 4
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Colorcon
AstraZeneca
McKesson
Dow
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.